Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Publications indexed to the term Dexamethasone

FacultyTitle
1Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. (Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martínez-López J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R) Lancet Oncol 2026 Feb;27(2):254-268       42 Citations
2The impact of adrenalectomy on metabolic outcomes of patients with mild autonomous cortisol secretion defined by low-dose dexamethasone suppression testing. (Kumar AL, Dream S, Shaik T, Doffek K, Conrardy R, Findling JW, Carroll TB, Zhang CD, Evans DB, Wang TS) Surgery 2026 Jan;189:109775       2 Citations
1Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma. (Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, Mendes J, Lee S, Lonardi C, Slaughter A, Lendvai N, Schecter JM, Chen D, Zhao M, Yeh TM, Leleu X, Puig N, Dytfeld D, Zamagni E, Weisel K, Karlin L, Delforge M, Corradini P, Mina R, Roeloffzen W, Sidana S) Adv Ther 2025 Oct;42(10):5023-5041       1 Citation
1Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database. (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, Varghese NE, He J, Kharat A, Lee S, Cost P, Potluri R, Koneru M, Patel N, Florendo E, Rodriguez-Otero P, Yong K) Cancer Med 2025 Aug;14(15):e71093       1 Citation
1The effect of intravenous dexamethasone on rebound pain after wrist and hand surgery under supraclavicular brachial plexus blockade: a randomized placebo-controlled trial. (Kang R, Bang YJ, Shim JW, Choi SJ, Kong SM, Hahm TS, Park J, Sim WS, Ko JS) Can J Anaesth 2025 Jul;72(7):1079-1089       3 Citations
1Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome. (Farias-Moeller R, Hanin A, Ahsan S, Brooks J, Caganap SD, Czeisler B, Cheuret E, Cocuzzo B, Hahn CD, Kyureghyan H, Marcoux MO, Mohamed R, Park C, Stern Zimmer M, Barun V, Lai YC, Hirsch LJ) Neurocrit Care 2025 Oct;43(2):563-571       13 Citations
4The effects of chronic sleep restriction on the hypothalamic-pituitary-adrenal axis and its interaction with abstinence from opioid use. (Everson CA, Szabo A, Olsen CM, Glaeser BL, Raff H) Sleep 2025 Sep 09;48(9)       7 Citations
1Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, He J, Kharat A, Cost P, Valluri S, Yong K) Blood Adv 2024 Oct 08;8(19):5062-5071       17 Citations
1Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score-weighted, retrospective assessment. (Paw Cho Sing E, Tomlinson GA, Schechter T, Ali M, Phelan R, Rassekh SR, McKinnon K, Bier GA, van de Wetering M, Gomez S, Sung L, Dupuis LL) Support Care Cancer 2024 Jul 25;32(8):552       1 Citation
2Outcomes of a dexamethasone-prednisone combination treatment course for status asthmaticus. (Nelipovich S, Vepraskas SH, Soung P, Pronko K, Yan K, Zhang L, Porada K, Chou E) J Asthma 2024 Dec;61(12):1646-1654       1 Citation
2Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. (Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM) Blood Cancer J 2024 Apr 22;14(1):69       36 Citations
3Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) Lancet Haematol 2023 Nov;10(11):e890-e901       166 Citations
1High prevalence of frailty in patients with adrenal adenomas and adrenocortical hormone excess: a cross-sectional multi-centre study with prospective enrolment. (Dogra P, Šambula L, Saini J, Thangamuthu K, Athimulam S, Delivanis DA, Baikousi DA, Nathani R, Zhang CD, Genere N, Salman Z, Turcu AF, Ambroziak U, Garcia RG, Achenbach SJ, Atkinson EJ, Singh S, LeBrasseur NK, Kastelan D, Bancos I) Eur J Endocrinol 2023 Sep 01;189(3):318-326       35 Citations
2Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. (Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D) Clin Cancer Res 2023 Dec 01;29(23):4784-4796       28 Citations
1Flushing After Lumbar Epidural Steroid Injection with Dexamethasone. (Shermon S, Van Acker G, Suric V, Kim C, Abd-Elsayed A, Mata N) Curr Pain Headache Rep 2023 Jun;27(6):143-148       3 Citations
2Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. (Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S) Cancer 2023 Jul 15;129(14):2179-2191       8 Citations
2Drug-resistant seizures associated with hyperinflammatory monocytes in FIRES. (Howe CL, Johnson RK, Overlee BL, Sagen JA, Mehta N, Farias-Moeller R) Ann Clin Transl Neurol 2023 May;10(5):719-731       24 Citations
1Aim for zero: prevention of postoperative nausea and vomiting using an off-patent five-drug multimodal approach. (Williams BA, Holder-Murray JM, Nettrour JF, Ibinson JW, DeRenzo JS, Dalessandro C, Kentor ML, Herlich A) Br J Anaesth 2023 Jul;131(1):e1-e4       16 Citations
1Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. (Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM) Transplant Cell Ther 2023 Mar;29(3):174.e1-174.e10       60 Citations
1Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases. (Dispenzieri A, Zonder J, Hoffman J, Wong SW, Liedtke M, Abonour R, D'Souza A, Lee C, Cote S, Potluri R, Ammann E, Tran N, Lam A, Nair S) Amyloid 2023 Jun;30(2):161-168       6 Citations
2Standardization of Outcome Measures for Intratympanic Steroid Treatment for Idiopathic Sudden Sensorineural Hearing Loss. (Osafo NK, Friedland DR, Harris MS, Adams J, Davis C, Osinski K, Tong L, Luo J) Otol Neurotol 2022 Dec 01;43(10):1137-1143       8 Citations
2Current Practice and Rationale of Prescribing Dexamethasone for Pediatric Patients Hospitalized for Asthma. (Nelipovich S, Porada K, Vepraskas S, Soung P, Chou E) WMJ 2022 Apr;121(1):30-35       4 Citations
1Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. (Nathwani N, Bell J, Cherepanov D, Sowell FG, Shah R, McCarrier K, Hari P) Support Care Cancer 2022 Jul;30(7):5859-5869       17 Citations
3Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) J Clin Oncol 2022 Sep 01;40(25):2901-2912       230 Citations
2Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. (Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A) Transplant Cell Ther 2022 Feb;28(2):83.e1-83.e9       23 Citations
1Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. (Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW, COV-BARRIER Study Group) Lancet Respir Med 2021 Dec;9(12):1407-1418       629 Citations
1Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. (Hu W, Jiang C, Kim M, Yang W, Zhu K, Guan D, Lv W, Xiao Y, Wilson JR, Rader DJ, Pui CH, Relling MV, Lazar MA) Cell Metab 2021 Aug 03;33(8):1592-1609.e7       31 Citations
1Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. (Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG) Leukemia 2021 Dec;35(12):3526-3533       20 Citations
1Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. (Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB) Eur J Haematol 2021 Sep;107(3):301-310       5 Citations
1Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. (Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP) J Clin Oncol 2020 Aug 10;38(23):2628-2638       85 Citations
1Corticosteroid Guidance for Pregnancy during COVID-19 Pandemic. (McIntosh JJ) Am J Perinatol 2020 Jun;37(8):809-812       45 Citations
5Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN) Cancer 2020 Jun 15;126(12):2791-2801       5 Citations
1In vivo vascular rarefaction and hypertension induced by dexamethasone are related to phosphatase PTP1B activation not endothelial metabolic changes. (Herrera NA, Duchatsch F, Kahlke A, Amaral SL, Vasquez-Vivar J) Free Radic Biol Med 2020 May 20;152:689-696       13 Citations
1Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. (Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA) Clin Cancer Res 2020 May 15;26(10):2297-2307       44 Citations
1Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. (Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Paul Bowman W, Larsen E, Pullen J, Carroll A, Willman C, Hunger SP, Carroll WL, Camitta BM) Leukemia 2020 Apr;34(4):1006-1016       11 Citations
4Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 Jul 29;9(8):56       20 Citations
1Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. (Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH) Leuk Res 2019 Aug;83:106172       18 Citations
1Administration of dexamethasone disrupts endometrial receptivity by alteration of expression of miRNA 223, 200a, LIF, Muc1, SGK1, and ENaC via the ERK1/2-mTOR pathway. (Shariati MBH, Niknafs B, Seghinsara AM, Shokrzadeh N, Alivand MR) J Cell Physiol 2019 Nov;234(11):19629-19639       29 Citations
2Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG) Leukemia 2019 Jul;33(7):1736-1746       45 Citations
2Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. (Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A) J Clin Oncol 2019 Mar 01;37(7):589-597       242 Citations
1Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data. (Mitta A, Curtis BR, Reese JA, George JN) Am J Hematol 2019 Mar;94(3):E76-E78       44 Citations
1Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. (Patki M, McFall T, Rosati R, Huang Y, Malysa A, Polin L, Fielder A, Wilson MR, Lonardo F, Back J, Li J, Matherly LH, Bepler G, Ratnam M) Sci Rep 2018 Oct 30;8(1):16006       14 Citations
1Pericardial effusion in Hodgkin lymphoma: a report from the Children's Oncology Group AHOD0031 protocol. (Marks LJ, McCarten KM, Pei Q, Friedman DL, Schwartz CL, Kelly KM) Blood 2018 Sep 13;132(11):1208-1211       15 Citations
1Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. (Hari P, Lin HM, Zhu Y, Berg D, Richardson PG, Moreau P) J Med Econ 2018 Aug;21(8):793-798       7 Citations
1Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. (Parzuchowski A, Bush R, Pei Q, Friedman DL, FitzGerald TJ, Wolden SL, Dharmarajan KV, Constine LS, Laurie F, Kessel SK, Appel B, Fernandez K, Punnett A, Schwartz CL, Cox J, Terezakis SA) Int J Radiat Oncol Biol Phys 2018 Apr 01;100(5):1119-1125       6 Citations
1The effect of postoperative steroids on post-tonsillectomy pain and need for postoperative physician contact. (Redmann AJ, Maksimoski M, Brumbaugh C, Ishman SL) Laryngoscope 2018 Sep;128(9):2187-2192       24 Citations
5Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350       148 Citations
1Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. (Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P) Haematologica 2017 Oct;102(10):1767-1775       48 Citations
1Diagnosis and Differential Diagnosis of Cushing's Syndrome. (Findling JW, Nieman L, Tabarin A) N Engl J Med 2017 Jul 13;377(2):e3       7 Citations
1Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. (Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG) Br J Haematol 2017 Aug;178(4):571-582       66 Citations
1Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. (Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S) Clin Cancer Res 2017 Jul 01;23(13):3307-3315       233 Citations
1Successful treatment of recurrent CNS disease post-bone marrow transplant in children with familial hemophagocytic lymphohistiocytosis. (Bock AM, LeVeque M, Camitta B, Talano JA) Pediatr Blood Cancer 2016 Dec;63(12):2154-2158       4 Citations
1Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. (Chen Z, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX, Wang Q) Nat Commun 2015 Sep 16;6:8323       89 Citations
4Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3       14 Citations
2Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG) Lancet Oncol 2014 Dec;15(13):1503-1512       263 Citations
1Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. (Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL) J Clin Oncol 2014 Nov 10;32(32):3651-8       245 Citations
1Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. (Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S) Cancer Chemother Pharmacol 2014 Oct;74(4):875-82       35 Citations
1Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). (Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP) Haematologica 2014 Sep;99(9):1479-85       121 Citations
1Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. (Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M) J Thorac Oncol 2014 Apr;9(4):519-26       29 Citations
2Dexamethasone for acute asthma exacerbations in children: a meta-analysis. (Keeney GE, Gray MP, Morrison AK, Levas MN, Kessler EA, Hill GD, Gorelick MH, Jackson JL) Pediatrics 2014 Mar;133(3):493-9       116 Citations
1Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. (Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E) J Clin Oncol 2013 Sep 01;31(25):3076-82       303 Citations
1Painting blood vessels and atherosclerotic plaques with an adhesive drug depot. (Kastrup CJ, Nahrendorf M, Figueiredo JL, Lee H, Kambhampati Thiruvengadam S, Lee T, Cho SW, Gorbatov R, Iwamoto Y, Dang TT, Dutta P, Yeon JH, Cheng H, Pritchard CD, Vegas AJ, Siegel CD, MacDougall S, Okonkwo M, Thai A, Stone JR, Coury AJ, Weissleder R, Langer R, Anderson DG) Proc Natl Acad Sci U S A 2012 Dec 26;109(52):21444-9       124 Citations
1Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. (Hogg RJ, Friedman A, Greene T, Radeva M, Budisavljevic MN, Gassman J, Gipson DS, Jefferson JA, John EG, Kaskel FJ, Moudgil A, Moxey-Mims M, Ortiz LA, Schelling JR, Schnaper W, Srivastava T, Trachtman H, Vehaskari VM, Wong C, Woronieki RP, Van Why SK, Zolotnitskaya A) Clin J Am Soc Nephrol 2013 Feb;8(2):211-8       20 Citations
1Impact of maternal dexamethasone on coronary PGE(2) production and prostaglandin-dependent coronary reactivity. (Roghair RD, Volk KA, Lamb FS, Segar JL) Am J Physiol Regul Integr Comp Physiol 2012 Sep 01;303(5):R513-9       3 Citations
1Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. (Twombley K, Pokala H, Ardura MI, Harker-Murray P, Johnson-Welch SF, Weinberg A, Seikaly M) Pediatr Transplant 2012 Sep;16(6):E201-9       16 Citations
1Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression. (Grunewald M, Johnson S, Lu D, Wang Z, Lomberk G, Albert PR, Stockmeier CA, Meyer JH, Urrutia R, Miczek KA, Austin MC, Wang J, Paul IA, Woolverton WL, Seo S, Sittman DB, Ou XM) J Biol Chem 2012 Jul 13;287(29):24195-206       86 Citations
1Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. (Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV) Blood 2012 May 10;119(19):4375-82       419 Citations
1Toxicogenomic analysis of a sustained release local anesthetic delivery system. (Shichor I, Shomron N, Lawlor MW, Bae SA, Zoldan J, Langer R, Kohane DS) Biomaterials 2012 May;33(13):3586-93       11 Citations
3Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN)) Lancet Oncol 2011 Dec;12(13):1195-203       269 Citations
2Treatment of recurrent CNS disease post-bone marrow transplant in familial HLH. (Rangarajan HG, Grochowski D, Mulberry MF, Gheorghe G, Camitta BM, Talano JA) Pediatr Blood Cancer 2012 Jul 15;59(1):189-90       2 Citations
1Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. (Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen DJ, Shuster J, Willman CL, Winick N, Camitta BM, Hunger SP, Borowitz MJ) Pediatr Blood Cancer 2011 Oct;57(4):569-77       59 Citations
1Multimodality imaging of abnormal vascular perfusion and morphology in preclinical 9L gliosarcoma model. (Darpolor MM, Molthen RC, Schmainda KM) PLoS One 2011 Jan 31;6(1):e16621       16 Citations
1Effect of insulin and dexamethasone on fetal assimilation of maternal glucose. (Norris AW, Wang C, Yao J, Walsh SA, Sawatzke AB, Hu S, Sunderland JJ, Segar JL, Ponto LL) Endocrinology 2011 Jan;152(1):255-62       16 Citations
1Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. (Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP) Endocrinology 2010 Oct;151(10):4811-9       286 Citations
1Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. (Blumenkranz MS, Haller JA, Kuppermann BD, Williams GA, Ip M, Davis M, Weinberg DV, Chou C, Whitcup SM) Retina 2010;30(7):1090-4       44 Citations
1Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. (Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV) Leukemia 2010 Jul;24(7):1350-6       77 Citations
1Coronary endothelial function and vascular smooth muscle proliferation are programmed by early-gestation dexamethasone exposure in sheep. (Volk KA, Roghair RD, Jung F, Scholz TD, Lamb FS, Segar JL) Am J Physiol Regul Integr Comp Physiol 2010 Jun;298(6):R1607-14       5 Citations
1Intravitreous dexamethasone effects on different patterns of diabetic macular edema. (Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS, Dexamethasone DDS Phase II Study Group) Arch Ophthalmol 2010 May;128(5):642-3       29 Citations
1Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. (Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group) Arch Ophthalmol 2010 Mar;128(3):289-96       279 Citations
1Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. (Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM) Leuk Lymphoma 2010 Feb;51(2):243-51       15 Citations
1Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. (Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group) Am J Ophthalmol 2009 Jun;147(6):1048-54, 1054.e1-2       190 Citations
1Dexamethasone promotes calcium pyrophosphate dihydrate crystal formation by articular chondrocytes. (Fahey M, Mitton E, Muth E, Rosenthal AK) J Rheumatol 2009 Jan;36(1):163-9       15 Citations
1Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. (Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM) Retina 2009 Jan;29(1):46-51       97 Citations
1Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. (Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL) J Clin Oncol 2008 Aug 20;26(24):3971-8       205 Citations
1Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. (Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, Shaw BE, Saso RM, Dines S, Morgan GJ) Eur J Haematol 2008 Dec;81(6):432-6       22 Citations
2Late-night salivary cortisol measurement in the diagnosis of Cushing's syndrome. (Carroll T, Raff H, Findling JW) Nat Clin Pract Endocrinol Metab 2008 Jun;4(6):344-50       83 Citations
1Coronary constriction to angiotensin II is enhanced by endothelial superoxide production in sheep programmed by dexamethasone. (Roghair RD, Miller FJ Jr, Scholz TD, Lamb FS, Segar JL) Pediatr Res 2008 Apr;63(4):370-4       10 Citations
1The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. (Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM) J Clin Endocrinol Metab 2008 May;93(5):1526-40       2427 Citations
3Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. (Kidambi S, Raff H, Findling JW) Eur J Endocrinol 2007 Dec;157(6):725-31       122 Citations
1Combination of antiemetics for the prevention of postoperative nausea and vomiting in high-risk patients. (Kim EJ, Ko JS, Kim CS, Lee SM, Choi DH) J Korean Med Sci 2007 Oct;22(5):878-82       22 Citations
2Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? (Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A) J Oncol Pharm Pract 2007 Jun;13(2):69-75       24 Citations
1Murine aortic reactivity is programmed equally by maternal low protein diet or late gestation dexamethasone. (Roghair RD, Segar JL, Kilpatrick RA, Segar EM, Scholz TD, Lamb FS) J Matern Fetal Neonatal Med 2007 Nov;20(11):833-41       15 Citations
1Endothelial superoxide production is altered in sheep programmed by early gestation dexamethasone exposure. (Roghair RD, Miller FJ Jr, Scholz TD, Lamb FS, Segar JL) Neonatology 2008;93(1):19-27       23 Citations
1Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. (Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group) Arch Ophthalmol 2007 Mar;125(3):309-17       410 Citations
1Glucocorticoid feedback control of corticotropin in the hypoxic neonatal rat. (Raff H, Jacobson L) J Endocrinol 2007 Feb;192(2):453-8       8 Citations
1Early gestation dexamethasone alters baroreflex and vascular responses in newborn lambs before hypertension. (Segar JL, Roghair RD, Segar EM, Bailey MC, Scholz TD, Lamb FS) Am J Physiol Regul Integr Comp Physiol 2006 Aug;291(2):R481-8       38 Citations
2Cushing's Syndrome: important issues in diagnosis and management. (Findling JW, Raff H) J Clin Endocrinol Metab 2006 Oct;91(10):3746-53       263 Citations
1Adiponectin and resistin in the neonatal rat: effects of dexamethasone and hypoxia. (Raff H, Bruder ED) Endocrine 2006 Apr;29(2):341-4       23 Citations
1Newborn lamb coronary artery reactivity is programmed by early gestation dexamethasone before the onset of systemic hypertension. (Roghair RD, Segar JL, Sharma RV, Zimmerman MC, Jagadeesha DK, Segar EM, Scholz TD, Lamb FS) Am J Physiol Regul Integr Comp Physiol 2005 Oct;289(4):R1169-76       34 Citations
1Plasma leptin and ghrelin in the neonatal rat: interaction of dexamethasone and hypoxia. (Bruder ED, Jacobson L, Raff H) J Endocrinol 2005 Jun;185(3):477-84       30 Citations
2Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters. (Quarles CC, Krouwer HG, Rand SD, Schmainda KM) Technol Cancer Res Treat 2005 Jun;4(3):245-9       18 Citations
1Diets containing soy protein isolate increase hepatic CYP3A expression and inducibility in weanling male rats exposed during early development. (Ronis MJ, Chen Y, Jo CH, Simpson P, Badger TM) J Nutr 2004 Dec;134(12):3270-6       18 Citations
1Dexamethasone treatment in the newborn rat: fatty acid profiling of lung, brain, and serum lipids. (Bruder ED, Lee PC, Raff H) J Appl Physiol (1985) 2005 Mar;98(3):981-90       19 Citations
1Neonatal dexamethasone therapy: short- and long-term consequences. (Raff H) Trends Endocrinol Metab 2004 Oct;15(8):351-2       28 Citations
1Metabolic consequences of hypoxia from birth and dexamethasone treatment in the neonatal rat: comprehensive hepatic lipid and fatty acid profiling. (Bruder ED, Lee PC, Raff H) Endocrinology 2004 Nov;145(11):5364-72       28 Citations
1Early gestation dexamethasone programs enhanced postnatal ovine coronary artery vascular reactivity. (Roghair RD, Lamb FS, Miller FJ Jr, Scholz TD, Segar JL) Am J Physiol Regul Integr Comp Physiol 2005 Jan;288(1):R46-53       36 Citations
2The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. (Findling JW, Raff H, Aron DC) J Clin Endocrinol Metab 2004 Mar;89(3):1222-6       153 Citations
2Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. (Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM) Neuro Oncol 2003 Oct;5(4):235-43       65 Citations
1Effects of hypoxia on the development of intestinal enzymes in neonatal and juvenile rats. (Lee PC, Struve M, Raff H) Exp Biol Med (Maywood) 2003 Jun;228(6):717-23       9 Citations
1Cutaneous manifestations of hemophagocytic lymphohistiocytosis. (Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA) Arch Dermatol 2002 Sep;138(9):1208-12       90 Citations
1Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. (Lenzi R, Yalcin S, Evans DB, Abbruzzese JL) Cancer Invest 2002;20(4):464-72       41 Citations
1Neonatal hypoxia in the rat: effects on exocrine pancreatic development. (Lee PC, Struve M, Lewis SM, Raff H) J Pediatr Gastroenterol Nutr 2002 May;34(5):542-7       10 Citations
3Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. (Levin DS, Han DP, Dev S, Wirostko WJ, Mieler WF, Connor TB, George V, Eastwood D) Am J Ophthalmol 2002 Feb;133(2):196-202       50 Citations
1Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. (Broome HE, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM) Leuk Res 2002 Mar;26(3):311-6       30 Citations
1Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. (Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, Sallan SE) J Clin Oncol 2001 Feb 15;19(4):1040-6       54 Citations
1Which pharmacologic therapies are effective in preventing acute mountain sickness? (Meurer LN, Slawson JG) J Fam Pract 2000 Nov;49(11):981    
1Effect of neonatal hypoxia on the development of hepatic lipase in the rat. (Lee PC, Jelinek B, Struve M, Bruder ED, Raff H) Am J Physiol Regul Integr Comp Physiol 2000 Oct;279(4):R1341-7       17 Citations
1Tyrosine phosphorylation of focal adhesion kinase and paxillin regulates the signaling mechanism of the rapid nongenomic action of dexamethasone on actin cytoskeleton. (Koukouritaki SB, Gravanis A, Stournaras C) Mol Med 1999 Nov;5(11):731-42       49 Citations
1Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. (Wang W, Abbruzzese JL, Evans DB, Chiao PJ) Oncogene 1999 Aug 12;18(32):4554-63       153 Citations
1Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. (Alexanian AR, Bamburg JR) FASEB J 1999 Sep;13(12):1611-20       52 Citations
1A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. (Garland JS, Alex CP, Pauly TH, Whitehead VL, Brand J, Winston JF, Samuels DP, McAuliffe TL) Pediatrics 1999 Jul;104(1 Pt 1):91-9       144 Citations
1Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. (Beaupre DM, Talpaz M, Marini FC 3rd, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock R) Cancer Res 1999 Jun 15;59(12):2971-80       53 Citations
1Glucocorticoid effect on human mesangial cell cytoskeletal proteins. (Koukouritaki SB, Lianos EA) J Lab Clin Med 1999 Apr;133(4):378-83       11 Citations
2Newer diagnostic techniques and problems in Cushing's disease. (Findling JW, Raff H) Endocrinol Metab Clin North Am 1999 Mar;28(1):191-210       72 Citations
1Corticosterone facilitates the acquisition of cocaine self-administration in rats: opposite effects of the type II glucocorticoid receptor agonist dexamethasone. (Mantsch JR, Saphier D, Goeders NE) J Pharmacol Exp Ther 1998 Oct;287(1):72-80       113 Citations
1Effect of antenatal glucocorticoids on sympathetic nerve activity at birth in preterm sheep. (Segar JL, Lumbers ER, Nuyt AM, Smith OJ, Robillard JE) Am J Physiol 1998 Jan;274(1):R160-7       59 Citations
1Differential nitric oxide production by microvascular and macrovascular endothelial cells. (Geiger M, Stone A, Mason SN, Oldham KT, Guice KS) Am J Physiol 1997 Jul;273(1 Pt 1):L275-81       53 Citations
1Dexamethasone induces rapid actin assembly in human endometrial cells without affecting its synthesis. (Koukouritaki SB, Margioris AN, Gravanis A, Hartig R, Stournaras C) J Cell Biochem 1997 Jun 15;65(4):492-500       48 Citations
2Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. (Aron DC, Raff H, Findling JW) J Clin Endocrinol Metab 1997 Jun;82(6):1780-5       202 Citations
1Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. (Anene O, Meert KL, Uy H, Simpson P, Sarnaik AP) Crit Care Med 1996 Oct;24(10):1666-9       138 Citations
1Dexamethasone alters rapidly actin polymerization dynamics in human endometrial cells: evidence for nongenomic actions involving cAMP turnover. (Koukouritaki SB, Theodoropoulos PA, Margioris AN, Gravanis A, Stournaras C) J Cell Biochem 1996 Aug;62(2):251-61       69 Citations
1Psychological disturbance differentially alters CD4+ and CD8+ leukocytes in the blood and intrathecal compartments. (Hou FY, Coe CL, Erickson C) J Neuroimmunol 1996 Aug;68(1-2):13-8       10 Citations
1Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. (Yesner LM, Huh HY, Pearce SF, Silverstein RL) Arterioscler Thromb Vasc Biol 1996 Aug;16(8):1019-25       159 Citations
1The induction of hepatic cytochrome P450 3A in rats: effects of age. (Lee PC, Werlin SL) Proc Soc Exp Biol Med 1995 Nov;210(2):134-9       23 Citations
1Age and gender effect on the inducibility of steroid metabolizing cytochrome P450 in rat liver. (Lee PC, Struve MF, Werlin SL) Biochem Mol Biol Int 1994 Nov;34(5):861-70       9 Citations
1Biochemical and radiologic diagnosis of Cushing's syndrome. (Findling JW, Doppman JL) Endocrinol Metab Clin North Am 1994 Sep;23(3):511-37       113 Citations
1Transient leukemoid reaction in an extremely premature neonate. (Teng RJ, Chen BW, Ho MM) Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1994;35(3):225-8       4 Citations
1Secretion of adrenocorticotrophin (ACTH) and ACTH precursors in ovine anterior pituitary cells: actions of corticotrophin-releasing hormone, arginine vasopressin and glucocorticoids. (Schwartz J, Ash P, Ford V, Raff H, Crosby S, White A) J Endocrinol 1994 Feb;140(2):189-95       31 Citations
1Effects of fetal dexamethasone exposure on postnatal control of cardiac adenylate cyclase: beta-adrenergic receptor coupling to Gs regulatory protein. (Bian X, Seidler FJ, Olsen C, Raymond JR, Slotkin TA) Teratology 1993 Aug;48(2):169-77       18 Citations
1Nitric oxide mediates IL-1 beta-induced islet dysfunction and destruction: prevention by dexamethasone. (Corbett JA, Wang JL, Misko TP, Zhao W, Hickey WF, McDaniel ML) Autoimmunity 1993;15(2):145-53       84 Citations
1Cushing syndrome--an etiologic workup. (Findling JW, Mazzaferri EL) Hosp Pract (Off Ed) 1992 Oct 15;27(10):107-12, 114-8, 121-2       2 Citations
1Dexamethasone increases apolipoprotein A-I concentrations in medium and apolipoprotein A-I mRNA abundance from Hep G2 cells. (Varma VK, Smith TK, Sorci-Thomas M, Ettinger WH Jr) Metabolism 1992 Oct;41(10):1075-80       18 Citations
1Meta-analysis redux-steroids and meningitis revisited. (Havens PL) West J Med 1992 Jul;157(1):84-6       5 Citations
4Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. (Weissman DE, Janjan NA, Erickson B, Wilson FJ, Greenberg M, Ritch PS, Anderson T, Hansen RM, Chitambar CR, Lawton CA) J Neurooncol 1991 Dec;11(3):235-9       46 Citations
1Modulation of lingual lipase development by glucocorticoid in the rat. (Lee PC, Struve MF, Werlin SL) Pediatr Res 1991 Jan;29(1):46-9       5 Citations
2Cortisol inhibition of vasopressin and ACTH responses to arterial hypotension in conscious dogs. (Raff H, Skelton MM, Cowley AW Jr) Am J Physiol 1990 Jan;258(1 Pt 2):R64-9       8 Citations
1Adrenal blood flow and secretory relationships during hypoxia in anesthetized dogs. (Breslow MJ, Ball TD, Miller CF, Raff H, Traystman RJ) Am J Physiol 1989 Nov;257(5 Pt 2):H1458-65       6 Citations
2Feedback control of vasopressin and corticotrophin secretion in conscious dogs: effect of hypertonic saline. (Raff H, Skelton MM, Cowley AW Jr) J Endocrinol 1989 Jul;122(1):41-8       17 Citations
2A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome. (Raff H, Findling JW) Clin Chem 1989 Apr;35(4):596-600       147 Citations
1Regulation of the expression of the rat alcohol dehydrogenase gene by glucocorticoids. (Qulali M, Wolfla CE, Ross RA, Crabb DW) Prog Clin Biol Res 1989;290:143-53       1 Citation
1Experimental drug therapy of peritumoral brain edema. (Weissman DE, Stewart C) J Neurooncol 1988 Dec;6(4):339-42       25 Citations
1Induction of alcohol dehydrogenase activity and mRNA in hepatoma cells by dexamethasone. (Wolfla CE, Ross RA, Crabb DW) Arch Biochem Biophys 1988 May 15;263(1):69-76       47 Citations
2Inhibition of the adrenocorticotropin response to surgery in humans: interaction between dexamethasone and fentanyl. (Raff H, Norton AJ, Flemma RJ, Findling JW) J Clin Endocrinol Metab 1987 Aug;65(2):295-8       42 Citations
1Corticosteroid toxicity in neuro-oncology patients. (Weissman DE, Dufer D, Vogel V, Abeloff MD) J Neurooncol 1987;5(2):125-8       129 Citations
1Reversible inhibition of cytosolic glucocorticoid receptors by mercurial agents. Application in the measurement of total and unoccupied receptors. (Ellis D, Tran SD, Eagon PK, Avner ED) J Recept Res 1987;7(5):761-74       1 Citation
2Vasopressin responses to corticotropin releasing factor and hyperosmolality in conscious dogs. (Raff H, Skelton MM, Merrill DC, Cowley AW Jr) Am J Physiol 1986 Dec;251(6 Pt 2):R1235-9       18 Citations
1Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. (Lewis GD, Campbell WB, Johnson AR) Endocrinology 1986 Jul;119(1):62-9       89 Citations
1Partial characterization and ontogeny of renal cytosolic glucocorticoid receptors in mouse kidney. (Ellis D, Turocy JF, Sweeney WE Jr, Avner ED) J Steroid Biochem 1986 May;24(5):997-1003       10 Citations
1An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. (Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH) Ann Intern Med 1986 Feb;104(2):180-6       137 Citations
1Increased numbers of neuroepithelial bodies (NEB) in lungs of fetal rhesus monkeys following maternal dexamethasone treatment. (Dayer AM, Kapanci Y, Rademakers A, Rusy LM, De Mey J, Will JA) Cell Tissue Res 1985;239(3):703-5       8 Citations
1Cushing's syndrome: problems in diagnosis. (Aron DC, Tyrrell JB, Fitzgerald PA, Findling JW, Forsham PH) Medicine (Baltimore) 1981 Jan;60(1):25-35       88 Citations
1Transmembrane potential and amino acid transport in rat hepatocytes in primary monolayer culture. (Wondergem R, Harder DR) J Cell Physiol 1980 Jul;104(1):53-60       21 Citations